Thermo Fisher Scientific (TMO) is forming numerous strategic alliances, including a partnership with RoosterBio to strengthen cell therapy solutions and a collaboration center in San Diego for advanced therapies. They're driving innovation with the introduction of the 5L DynaDrive Single-Use Bioreactor and the Vulcan™ Automated Lab for semiconductor analysis. A notable investment for the company is the $2B US project to propel American Life Sciences. However, they've had to revise their 2025 profit forecast due to tariffs and research funding cuts, and job cuts are imminent at the Orlando location. Despite these challenges, analysts propose a potential upside of 35.79% and 35.63% for TMO stock. First quarter 2025 earnings have surpassed estimates while also reporting robust profits due to demand surge. Amid these developments, TMO continues to draw Billionaire investors like Ken Fisher, with its hefty dividend and large-cap value standing out. Recent acquisitions include Solventum’s Purification and Filtration Business for $4.1bn.
Thermo Fisher Scientific TMO News Analytics from Thu, 07 Nov 2024 08:00:00 GMT to Fri, 02 May 2025 14:13:02 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor 3
